Reply  by Valgimigli, Marco & Serruys, Patrick W.
ADVANCE Praise
Sometimes an artfully crafted quasi-acronym can help distinguish
one otherwise indistinguishable clinical advance from another
(1–3). The infectiousness of this engaging wOrdPlay is evidenced
by a recent report describing the role of Tirofiban for prevention of
iscHEmIc complicatioNS among high-risk pAtieNts undergoIng
coronary angioplasTY (4)—a distinguished advance indeed!
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REPLY
We thank Dr. Diamond for his interest in our recent paper (1).
It can happen that, when a trial is designed, not enough
attention is paid to the (quasi)-acronym used to identify the study.
Unfortunately, it also happens that the medical world finishes
paying more attention to it than to the trial message itself, and that
is not a distinguished advance indeed! But the lesson is clear: from
now on, we will keep ADVANC(E)ing with new STRAT-
EG(Y)ies (2).
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CORRECTION
Chessa M, Butera G, Carminati M. Letter to the Editor: Risk of Thrombus Formation on Devices Used to Close Transcatheter
Atrial Septal Defect and Patent Foramen Ovale. J Am Coll Cardiol 2004;44:1712.
The correct authors’ names are Massimo Chessa, MD, PhD, Gianfranco Butera, MD, PhD, and Mario Carminati, MD.
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